Visit https://www.peervoice.com/KYP860 to view the entire programme with slides. After completing “Optimising HBV Treatment Outcomes Whilst We Hunt for a Cure”, participants will be able to: Identify the importance of reducing hepatocellular carcinoma (HCC) risk and improving secondary outcomes in patients receiving viral suppressive therapy; Recognise that antiviral suppressive therapies may differ in their impact on HCC risk and secondary outcomes; Describe the latest data for suppressive therapies and their potential impact on treatment strategies.